PHILADELPHIA (MedPage Today) — Women who frequently sprayed their homes with insecticides over a period of years may have put themselves at risk for autoimmune diseases such as rheumatoid arthritis and lupus, a researcher said here.
No Comments »
Filed under: General Health News
PHILADELPHIA (MedPage Today) — Drugs intended to prevent osteoarthritis of the knee can realistically be cost-effective only if the annual expense per patient is substantially less than $1,000, researchers said here.
No Comments »
Filed under: General Health News
WASHINGTON (MedPage Today) — A procedural vote on the bill that would provide a “doctors’ payment fix” has failed in the Senate, sending the message that the bill does not have the necessary votes to become law.
No Comments »
Filed under: General Health News
The physician workforce in the U.S. has begun to grow smaller and younger, according to data from the Census Bureau.
No Comments »
Filed under: General Health News
Important information is often missing from drug labels, two Dartmouth Medical School researchers said.
No Comments »
Filed under: Pharmacy News
KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm’s proprietary ligand [...]
No Comments »
Filed under: Pharmacy News
Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive results from a Phase 2a study of its Rho-kinase (ROCK) inhibitor, AR-12286. The study evaluated the safety, tolerability and efficacy of three different doses of AR-12286 in 88 patients with primary open angle glaucoma or ocular [...]
No Comments »
Filed under: Pharmacy News
AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical trial of ARX-03, a proprietary sublingual dosage form combining an opioid, sufentanil, with a benzodiazepine, triazolam.
No Comments »
Filed under: Pharmacy News
PacificGMP, the leader in single-use bioprocessing for development and manufacturing for its client partners, announced that ArmaGen Technologies has selected it to produce its proprietary protein for a Phase 1 clinical trial.
No Comments »
Filed under: Pharmacy News
Pharmos Corporation (Pink Sheets: PARS); on September 14, 2009, Pharmos announced the results of its Phase 2b Dextofisopam trial for the treatment of diarrhea predominant and alternating diarrhea and constipation irritable bowel syndrome.
No Comments »
Filed under: Pharmacy News
